Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
about
Galeterone for the treatment of advanced prostate cancer: the evidence to dateResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Emerging Variants of Castration-Resistant Prostate Cancer.Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Current perspectives on bone metastases in castrate-resistant prostate cancer.Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer.Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.Androgen action in prostate function and disease.Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
P2860
Q26739887-48B05C76-0BF9-41C9-AB58-4C0A62D91047Q26751237-E419DE4E-1C1E-4BF4-B892-D3F43C962DCFQ36398998-E6002ACD-B1BB-4814-8569-22BF123446C7Q36862668-D4188E2C-BC92-449F-A238-103CD95E6833Q37417870-2B5CCCD6-AF78-45D7-A88E-26D834844274Q37595372-C1ADE584-C3F6-4B72-90F0-F0AD2213FD61Q38720538-7E7A468D-0889-4DA3-BCBB-2649C03E9C7AQ38722705-BD171566-73C8-410A-861B-51C321B12016Q38836163-0C71C7CE-82C8-4172-9E4A-F6730513EE63Q38930155-4F107942-8B12-44E1-A6E0-598B57917970Q38966736-BC20DDE8-074B-46BE-9310-FC3EC2346D52Q39210257-461100B4-F8C3-4918-89A8-EE457E624D85Q43578455-B943ED09-0D7F-4A00-B7A7-F7F90453AA6EQ47231171-FFBA7ACB-6BB8-4914-ADA2-B44096D1C664Q47595568-A39F8E59-5509-4DBE-B6AC-1D8967817762Q47740995-AEC9FAFD-EE0C-498A-BF3C-F31435C25E7EQ49285273-62F2FBAE-DDDA-4BE0-B9E2-ADF89546E12AQ53700061-4BD40508-8B7A-4802-B2F5-BDC336864432Q53741551-972018DF-9677-4EA3-8877-E524BC61FB32Q55171826-8CD60747-67EA-43C1-89AF-3DCE4DD8BB9AQ55251761-7FFF8ACC-ED9C-4E5D-9204-1A0B9623247AQ55343494-998BAD0B-1F2C-4CC1-895E-5AA2ED704F43Q58603582-0F703288-B28D-4B4C-A5EC-40EC134EABBD
P2860
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@en
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@nl
type
label
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@en
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@nl
prefLabel
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@en
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@nl
P2093
P2860
P1476
Combined Tumor Suppressor Defe ...... sive Variant Prostate Cancers.
@en
P2093
Ana M Aparicio
Bradley Broom
Christopher J Logothetis
Elsa Li Ning Tapia
Guanglin Wu
Hsiang-Chun Chen
Jiexin Zhang
Jing-Fang Lu
Keith Baggerly
P2860
P304
P356
10.1158/1078-0432.CCR-15-1259
P407
P577
2015-11-06T00:00:00Z